Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yigongsan Granules Phase IIa in CKD-related anemia (spleen qi deficiency)
CTR20254620Phase 2Active
- Sponsor
- China Shenwei Pharmaceutical Group
- Start
- Mar 2026
- Countries
- 1
01
Overview
A Phase 2 trial of yigongsan in anemia of inflammation (AI), chronic kidney disease (CKD), sponsored by China Shenwei Pharmaceutical Group. Started Mar 2026; status: active.
02
Drugs
yigongsan
03
Conditions
anemia of inflammation (AI)chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20254620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254620.